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as few as 3 visits or to never achieve target and undergo
10 visits. Total costs include costs of study drug, add-on
therapy, physician office visits, lab tests and attributable
adverse events. Costs for physician office visits in Spain
(GP) were 1 327 pts and costs for lipid panels were 4 090
pts. RESULTS: Patients treated with atorvastatin achieved
LDL-C target significantly faster (P  0.05) at lower
doses of study drug and required significantly fewer clinic
visits than patients treated with comparator statins. Con-
sequently, mean total cost of care to reach LDL-C targets
were significantly lower than costs for patients treated
with comparators (P  0.05). CONCLUSION: Costs for
treating patients to LDL-C targets with HMG-CoA re-
ductase inhibitors varied significantly among drugs. To-
tal costs of therapy in Spain were lowest with atorvastatin,
when compared to other reductase inhibitors examined
in this study.
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OBJECTIVES: The purpose of this study is to determine
the annual economic burden of stroke, given that cere-
brovascular disease is one of the leading causes of death
and disability in Greece. METHODS: Retrospective da-
tabase selection was made regarding patients with stroke,
hospitalized in Greek hospitals. We modeled the disease
based on the existing epidemiological, demographic, clin-
ical and economic data in order to estimate direct and in-
direct cost by stroke type, degree of severity, age group
and deaths. Clinical data derive from National Statistical
Service of Greece. Incidence and prevalence data are
based on Greek experts’ published reports. Inpatient
care unit costs, sickness funds payments, patient’s out-of-
pocket money and any other expenses are based on prices
set by the Ministry of Labour. Cost analysis is based on
one-year patient treatment and survival. RESULTS: An-
nual direct cost per patient is $6,700 including hospital-
pharmaceutical care, laboratory-diagnostic tests, outpa-
tient’s visits and rehabilitation. Percentage distribution is
45% hospital care, 30% rehabilitation, 10% diagnostic
tests, 9% pharmaceutical care and 6% consultation. The
annual burden to the sickness funds is estimated at
$7,000 per severe event and $2,000 per moderate event.
Losses from the societal perspective are estimated at
$25,700 for the severe and $6,300 for the moderate
event. CONCLUSIONS: Annual direct cost of stroke is
estimated at $170 million in Greece. Sickness funds cost
is $20,7 million while the societal burden is much higher
at $58,3 million due to chronic residual disabilities.
Given the considerable societal and economic impact of
stroke in Greece, enormous clinical and economic bene-
fits could be achieved through the expansion of second-
ary prevention, the adoption of economic evaluation
analyses regarding the various interventions and drug
therapies and finally through the creation of specialized
stroke units, non-existent in our country.
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OBJECTIVE: The GREAT (GRoup on Economic As-
sessment of hyperTension) study has the objective to esti-
mate the cost of care of hypertension study in Emilia Ro-
magna region and to evaluate the degree of blood pressure
(BP) control. METHODS: Twenty-seven GPs and 9 spe-
cialists centres participated in a previously reported
cross-sectional part of the study. Nine GPs and 2 special-
ists centres completed the longitudinal section of the
study. Demographic, clinical and economic information
was collected. Health care provided to patients has been
quantified in the perspective of the Italian National
Health Service (NHS), by means of tariffs. We report on
health care costs evaluated in the longitudinal section of
the study. All costs are presented as monthly costs and
expressed in Euros (1€  1936.27 ITL). RESULTS: 106
patients were assessed in the longitudinal study, 46
women (mean age 63  12) and 60 men (63  10). The
average follow-up period was 202  68 days and there
was one death. Fifty-eight (55%) patients had comorbid-
ities, 13 (12%) were smokers. The mean levels of SBP
and DBP were 138  35 and 81  20 mmHG at inclu-
sion and 134  31 and 79  23 mmHg at the end of the
study. More than 56% of the subjects obtained a satis-
factory control of BP (SBP  140 and DBP  90) and
27.4% of the patients reached an optimal control (SBP 
135 and DBP  85). The average monthly cost of hyper-
tension care per-patient over the follow-up period was
47.2€. Drugs represent the largest part of costs (30.0€,
63%), followed by physician’s visits (8.9€, 19%) diag-
nostics (3.2€, 7%), hospitalization (2.7€, 5%) and lab
tests (2.4€, 5%). CONCLUSIONS: During the observa-
tion period the majority of patients reached a satisfactory
control of BP. Drugs costs represent the most relevant
cost item among health care cost, probably due to the
time horizon of this study (on average seven months).
